ERBB2 and breast cancer: Increasing evidence suggest that the immune cells in the tumor microenvironment can modulate tumor response to chemotherapy and anti-HER2 targeted therapies.[39,40] Higher tumor-infiltraing lymphocytes (TILs) have been associated with both increased likelihood of pCR following NAC[41] and with improved prognosis[42] in early HER2-positive BC.